Last Price
1.49
Today's Change
-0.06 (3.87%)
Day's Change
1.49 - 1.65
Trading Volume
40,201
Market Cap
2 Million
Shares Outstanding
1 Million
Avg Volume
2,467,186
Avg Price (50 Days)
2.16
Avg Price (200 Days)
3.86
PE Ratio
-0.17
EPS
-8.73
Earnings Announcement
07-Nov-2024
Previous Close
1.55
Open
1.58
Day's Range
1.49 - 1.65
Year Range
1.35 - 7.6
Trading Volume
40,291
1 Day Change
-3.87%
5 Day Change
-11.83%
1 Month Change
-36.86%
3 Month Change
-54.71%
6 Month Change
-72.20%
Ytd Change
-70.90%
1 Year Change
-78.59%
3 Year Change
-99.32%
5 Year Change
-99.91%
10 Year Change
-100.00%
Max Change
-100.00%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.